Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Core Insights - Immunic, Inc. is a late-stage biotechnology company focused on developing novel oral therapies for neurologic and gastrointestinal diseases [3] - The company will participate in the 8th Annual Evercore ISI Healthcare Conference, with CEO Daniel Vitt scheduled for a fireside chat on December 4, 2025 [1][2] Company Overview - Immunic's lead program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [3] - Vidofludimus calcium acts as a first-in-class nuclear receptor related 1 (Nurr1) activator, providing neuroprotective effects and anti-inflammatory properties by inhibiting dihydroorotate dehydrogenase (DHODH) [3] - The company is also developing IMU-856, targeting Sirtuin 6 (SIRT6) to restore intestinal barrier function, with potential applications in various gastrointestinal diseases [3] - IMU-381 is in preclinical testing as a next-generation molecule for gastrointestinal diseases [3]